Charleen O’Keeffe


+353 1 489 6694 vCard Linkedin

Charleen is a Partner in William Fry's Litigation & Dispute Resolution Department and a member of its Life Sciences Group, specialising in intellectual property and regulatory law.

Charleen is a skilled commercial litigator, with extensive experience in complex, multi-jurisdictional intellectual property disputes. Her patent litigation experience ranges from pharmaceutical and biologics to a wide range of technologies including hi-tech and medical devices.

She advises in the areas of pharmaceuticals, biotechnology and medical devices, covering every phase of a product's life cycle from product development, clinical trials, data exclusivity, regulatory approval to commercialisation and product safety/recall/liability.

Recent significant cases include representing:

  • Genentech Inc in Commercial Court proceedings against Amgen relating to Amgen's product Mvasi®, a biosimilar of Genentech's leading cancer drug Avastin®.
  • Eli Lilly in complex multi-jurisdictional patent revocation proceedings against Eisai R&D Management Co (relating to the treatment of Alzheimer's disease). 
  • Boehringer Ingelheim in the defence of patent and SPC revocation proceedings brought by Teva Pharmaceuticals.
  • GlaxoSmithKline ("GSK") in Commercial Court patent infringement proceedings against Pfizer (relating to GSK's MenB vaccine, BEXERO).  
  • GSK in its trade mark and passing off action against Rowex Limited involving the Seretide Inhaler, one of the all-time best-selling prescription drugs.
  • BSA | The Software Alliance, the leading advocate for the global software industry, in its role as an amicus curia in the ongoing ground-breaking "Schrems II" litigation relating to the legality of the EU standard contractual clauses. 

Charleen is ranked as a 'Rising Star' with Managing Intellectual Property IP Stars 2020.

Charleen is described as ‘an original thinker’. Legal 500 EMEA 2018


Recommended Lawyer

TLR-Accred-white 2018